

Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique



Beatriz Manriquez Rocha^a, Francisco Mbofana^b, Osvaldo Loquiha^a, Chishamiso Mudenyanga^a, U. Vivian Ukah^c, Laura A. Magee^d, Peter von Dadelszen^{d,*}

^a Maternal, Newborn + Child Health, Clinton Health Access Initiative, Maputo, Mozambique

^b National Department of Public Health, Ministry of Health, Maputo, Mozambique

^c Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada

^d Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom

ARTICLE INFO

Keywords:

Preeclampsia
Stillbirth
Placental growth factor
Diagnostic performance
Operations research
Global health

ABSTRACT

In well-resourced settings, reduced circulating maternal free placental growth factor (PIGF) aids in either predicting or confirming the diagnosis of preeclampsia, fetal growth restriction, stillbirth, preterm birth, and delivery within 14 days of testing when pre-eclampsia is suspected. This operational pilot implementation of maternal plasma PIGF in women with suspected preeclampsia was conducted in six antenatal clinics in Maputo, Mozambique (six control clinics for comparison). The primary outcome was transfer to higher levels of care, following the informative PIGF assay. Of antenatal visits, 133/31,993 (0.42%) and 20/33,841 (0.06%) resulted in pre-eclampsia-related transfers of care for women attending intervention and control clinics, respectively ($p < .0001$). The clinic-to-delivery for women with low PIGF (< 100 pg/ml) interval was shorter, (vs normal PIGF (median 10 days [IQR 1–25] vs 36 [11–83], $p < .0001$)). Low PIGF was associated with younger maternal age, higher blood pressure, earlier delivery, more therapeutic interventions, preterm birth, lower birth weight, and perinatal loss. In addition, one-third of hypertensive women with PIGF < 50 pg/ml suffered a stillbirth. In urban Mozambican women with symptoms and/or signs suggestive of preeclampsia, low maternal plasma PIGF concentrations are associated with increased risks of adverse pregnancy outcomes, especially early delivery and stillbirth. Therefore, introducing PIGF into the clinical care of women with suspected preeclampsia was associated with increased transfers to higher levels of care; low PIGF (< 100 pg/ml) was associated with increased maternal and perinatal risks. PIGF < 50 pg/ml is particularly associated with stillbirth in women with suspected preeclampsia.

1. Introduction

Pregnancy hypertension, especially preeclampsia, remains a significant contributor to adverse maternal and perinatal events in sub-Saharan Africa [1,2]. Some women whose pregnancies are complicated by preeclampsia have evidence of angiogenic factor imbalance, with a surfeit of antiangiogenic factors (e.g., soluble fms-like tyrosine kinase-1 (sFlt-1)) and reduced proangiogenic factors (e.g., placental growth factor (PIGF)) [3–7].

Previously, we have confirmed the diagnostic performance of masked plasma PIGF in identifying women at increased risk of imminent delivery in clinics in Maputo, Mozambique [8]; through the identification of pregnancy complications beyond preeclampsia, such as fetal growth restriction of placental origin [9]. Therefore, we have proposed that PIGF should improve the provision of precision medicine

to individual women and improve pregnancy outcomes for those with preeclampsia or related placenta-mediated complications in all settings. Thereby, clinicians in all settings may be better able to triage women with suspected complications to optimize the care of those most at risk within stretched health systems.

After completion of this technical evaluation study, we designed and conducted a pilot implementation study in health centers to assess the impact of PIGF in aiding the diagnosis and time-of-disease risk stratification of preeclampsia, and, thereby, improving appropriate interventions for, and timely care of women with preeclampsia. In contrast to clinical research methods, which typically focus on the health effects of an evidence-based practice, implementation studies typically focus on rates and quality of use of evidence-based practices rather than their effects [10].

* Corresponding author at: Women Health Academic Centre, 10th Floor, North Wing, St. Thomas' Hospital, Westminster Bridge Rd, Lambeth, London SE1 7EH, United Kingdom.
E-mail address: pvd@kcl.ac.uk (P. von Dadelszen).

2. Methods

2.1. Study design and context

This operational pilot study was conducted with screening and testing of women from 26 April to 30 November 2016. In this context, the objective of this operational pilot was to assess the probable impact of large-scale implementation of an intervention, PIGF testing, within a health system.

All sites were in Maputo city, with six intervention sites (CS Bagamoyo, CS Chamanculo, CS Jose Macamo, CS Magoanine, CS 1 de Junho, CS 1 de Maio) and six control sites (CS Albazine, CS Catembe, CS Polana Canico, CS Pescadores, CS Xipamanine, CS Zimpeto). All sites offered prenatal care services, booked approximately 200 newly-identified pregnant women each month (i.e., 1400 new pregnancies per site), and had both on-site laboratory support and a maternity unit. CS Jose Macamo is associated with a general hospital. One site (CS 1 de Maio) has an ultrasound available, and CS Jose Macamo has access to the adjacent hospital's maternity unit ultrasound. The other four sites refer to the general hospital for ultrasounds, and any women referred need to use either public transport, car, or walk to get their ultrasound. Routine obstetric ultrasound was not offered at any sites, but limited to those deemed to be at high risk. Pregnancy dating was based upon last menstrual period and symphysis-fundal height. Intervention sites were matched, without randomization, to control sites based on antenatal clinic volume, maternity ward, type of support, electricity and laboratory. Referral centers were shared between intervention and control sites.

2.2. Intervention sites

All pregnant women, irrespective of age, attending the respective antenatal clinics of the six intervention sites were screened for hypertension by the attending nurse, and if any given pregnant woman < 37⁺⁰ weeks' pregnant presented with any evidence preeclampsia (i.e., high BP, proteinuria, signs or symptoms) she would be a candidate for the PIGF test.

BP was measured with women sitting and with the right arm supported at the level of the heart as part of routine prenatal care, using Microlife BP A2 Basic, (Microlife AG, Widnau, Switzerland) fully automated BP monitors. BP measurement was repeated if hypertension (defined as either a systolic BP \geq 140 mm Hg or a diastolic BP \geq 90 mm Hg) was detected on the first reading and the lower reading recorded in the data collection form. Normotensive readings were not repeated. The presence of significant proteinuria (\geq 2+ by dipstick) was not an eligibility criterion.

At the time of the prenatal visit that triggered eligibility (suspected preeclampsia), venous blood was collected by the clinic nurse, plasma prepared, and PIGF assayed using the Alere Triage[®] monoclonal antibody-based immunoassay and meter (Alere, San Diego, CA), according to the manufacturer's instructions by the on-site laboratory technician. Maternal plasma PIGF concentrations were quantified within the measurable range of the assay (12–3000 pg/ml) and classified as either normal (\geq 100 pg/ml) or low (< 100 pg/ml), as determined in our initial study [5]. Clinical and research staff were not blinded to the PIGF results.

Pregnant women with suspected preeclampsia remained on site until the PIGF result was available and the nurse could use the result to complement diagnosis and determine whether or not to initiate a referral. If women were assessed to be too unwell to either await PIGF results, or even to have the blood draw, they were referred immediately. On occasion, the blood draw was completed, but the transport arrived prior to knowledge of the PIGF result and the woman was referred to a tertiary facility without delay.

Facility management, including delivery decisions, was made by clinicians who were not involved in the study and in compliance with

Ministry of Health guidelines. The study protocol was approved by the National Bioethics Committee in Mozambique.

Patient information was collected from registries, patient charts and transfer logbooks at the prenatal care health facilities and maternity units. Dedicated study assistants were present at the intervention sites daily. They were stationed outside the antenatal clinic space and had access to all women screened for PIGF, to collect data at the time of screening. In addition, they were present when pregnant women returned for later antenatal visits or to the local maternity unit for delivery. Retrospective data were collected following delivery for women who delivered at referral maternity units. Two study assistants collected data two-to-three times a week to follow up transferred women, to ascertain whether or not they had been admitted or delivered, and the outcomes of mother and child. They attended the consulting rooms weekly, but did not interact with the women; rather, they relied solely on the available paper records (a more challenging task at referral facilities). In addition, they went weekly to search for data at referral facilities (these sites being the same referral sites for all the health centers). To support data collected from registries and patient charts, and fill in potential gaps due to deliveries occurring in the community, pregnant women enrolled in the intervention sites were contacted via either telephone or SMS, up to two times within the month after their due date of delivery.

2.3. Control sites

In the control sites, patient information was collected from registries and transfer logbooks at the prenatal care health facilities and maternity units. Two study assistants collected data two-to-three times a week, and patient chart data, including pregnancy outcomes, were not reviewed.

2.4. Outcomes

The primary outcome for analysis was transfer to higher levels of care, following the informative PIGF assay ('clinic'). Other outcomes of interest included: median time-to-delivery, confirmed diagnosis of preeclampsia, mode of delivery, intrauterine fetal death, and preterm birth (< 37⁺⁰ weeks). For outcome adjudication, preeclampsia was defined as hypertension and either significant proteinuria or other maternal organ dysfunction, according to the 2014 ISSHP criteria [11]. Adjudication of a diagnosis of preeclampsia was performed by obstetricians not involved in the women's care but taking into consideration the PIGF results.

2.5. Sample size

The sample size was determined considering that the pilot was a two-arm multi-site observational cohort, with six health facilities in each of the intervention and control arms. Assuming that PIGF would be able to diagnose about 25% more cases in the intervention sites than conventional care in the control sites (above a baseline prevalence of 35% in women with suspected preeclampsia in control sites), the sample size required for 80% power and 5% significance was 106 in each arm.

2.6. Statistical approach

Statistical analyses: Kaplan-Meier curves were derived and Mantel-Cox log-rank test survival analyses performed to describe the primary outcome. Fisher's exact and chi-square tests were used for categorical variables and Mann-Whitney U tests were used for continuous variables. To assess the performance of PIGF to identify women who suffered an intrauterine fetal death, an area under the receiver-operator curve (AUC ROC) analysis was performed. Using Prism 5.0 (GraphPad, San Diego, CA), statistical significance was set at $p < .05$ for the

primary comparison, and $p < .01$ for other comparisons (to adjust for multiple comparisons).

3. Results

During the seven months of the study, the diagnosis of preeclampsia was suspected in 278 and 194 women in intervention and control sites, respectively. These represent 0.87% of 31,993 and 0.57% of 33,841 antenatal visits in intervention and control sites, respectively (Yate’s-corrected $\chi^2 p < .0001$; relative risk 1.21 (95% confidence interval (CI) 1.13–1.31). In addition, this represents a 3.3% detection rate (assuming 8400 women receiving prenatal care in the six intervention sites), compared with a 2.3% (194/8400 women) suspected preeclampsia rate in six control sites (Yate’s-corrected $\chi^2 p = .0001$; relative risk 1.23 (95% CI 1.09–1.37)). Fetal heart sounds were detected using Pinard stethoscopes in all women at eligibility.

Maternal transfer to higher levels of care (primary outcome) was initiated for 133/278 (47.8%) and 20/194 (10.3%) of women in intervention and control sites, respectively (Yates-corrected $\chi^2 p = .0001$; relative risk 1.91 (95% CI 1.67–2.19)). These represent referral rates of 0.42% and 0.06% of antenatal visits in intervention and control sites, respectively (Yate’s-corrected $\chi^2 p < .0001$; relative risk 1.79 (95% CI 1.68–1.91).

Table 1 describes the baseline characteristics and outcomes of the 278 women with suspected preeclampsia attending for prenatal care at the intervention sites. Compared with 148 women with normal PIGF (≥ 100 pg/ml), the 130 women with low PIGF (< 100 pg/ml) were younger, at later gestational age when screened for PIGF, more severely hypertensive, more likely to have a confirmed diagnosis of preeclampsia by either proteinuria or symptoms, especially symptomatic preeclampsia, and more likely to have an increased number of prenatal visits (all $p < .01$); they tended to be more often nulliparous

($p = .0180$) and receive antihypertensive medication ($p = .0191$). This detail of clinical data was not available for the women who attended the control sites.

In terms of the clinic-to-delivery interval, women with low PIGF delivered more quickly (median: 10 days) compared with those with normal PIGF (median: 36 days) (Fig. 1(a)). Women with low PIGF delivered at earlier gestational ages (35 vs 37 weeks, respectively (Fig. 1(b))), more frequently preterm (85% vs 55%, respectively), and lighter infants (2.5 kg vs 3.1 kg, respectively). Only two (0.7%) women in this cohort received antenatal corticosteroids, although 117 of 278 (42.1%) women delivered before 35⁺⁰ weeks of pregnancy. Of the 160 (of 242 women who received antihypertensive agents) for whom the antihypertensive agents were recorded, 33 received solely methyldopa, while three received methyldopa and nifedipine, 100 received methyldopa and hydralazine and 21 received methyldopa, nifedipine and hydralazine. Three women received solely hydralazine.

There were three maternal deaths, two were women with normal PIGF (one of whom declined early referral to hospital and arrived moribund; the other declined to remain an inpatient and was lost to local follow-up (moved to South Africa)) and one with low PIGF (in-facility death in the regional tertiary hospital). Twenty-three percent of women with low PIGF suffered an intrauterine fetal death, compared with 6% of women with normal PIGF ($p < .0001$). Neonatal survival was similar between groups.

The area under the receiver-operator curve analysis of the performance determined that maternal PIGF predicted both intrauterine fetal death (AUC ROC = 0.78) and perinatal death (AUC ROC = 0.75) (Fig. 2). Thirty of 30 of 92 (32.6%) women with PIGF < 50 pg/ml suffered an intrauterine fetal death, compared with nine of 177 (5.1%) women with PIGF ≥ 50 pg/ml (Yates-corrected $\chi^2 p < .0001$). Using that cut-off of < 50 pg/ml, maternal plasma PIGF has a sensitivity of 76.9% (95% CI 60.7–88.9%) and specificity of 74.1% (95% CI

Table 1
Baseline characteristics and outcomes (n (%) or median (interquartile range)).

| Characteristic | Intervention sites | | P-value |
|---|---------------------------------|------------------------------|------------|
| | PIGF ≥ 100 pg/mL (n = 148) | PIGF < 100 pg/mL (n = 130) | |
| <i>Baseline characteristics</i> | | | |
| Maternal age, yr | 29 (24–34) | 27 (22–31) | .0061 |
| Nulliparous, Y | 28 (18.9) | 41 (31.5%) | .0180 |
| Maternal weight, kg | 70 (62–80) (n = 146) | 71 (62–79) (n = 127) | .6944 |
| Twin pregnancy, Y | 2 (1.4%) | 7 (5.4%) | .0875 |
| Gestational age at recruitment, wk | 30 (25–34) | 33 (29–35) | .0002 |
| Blood pressure at recruitment | | | |
| systolic blood pressure, mmHg | 150 (142–162) | 157 (146–172) | .0004 |
| diastolic blood pressure, mmHg | 94 (90–100) | 101 (94–111) | $< .0001$ |
| Preeclampsia, Y | 135 (91.2%) | 130 (100%) | .0002 |
| proteinuria $\geq 1+$ | 32 (21.6%) | 67 (51.5%) | $< .0001$ |
| preeclampsia symptoms, Y | 102 (74.9%) | 112 (88.2%) | .0021 |
| preeclampsia symptoms, n | 1 (0–2) | 2 (1–3) | $< .0001$ |
| New diagnosis of HIV in this pregnancy, Y | 39 (21.3%) | 30 (19.6%) | .7865 |
| Serum PIGF, pg/mL | 355 (186–828) | 25.8 (≤ 12.0 –58.9) | $< .0001$ |
| <i>Interventions received</i> | | | |
| Number of prenatal visits, n | 3 (1–4) | 3 (2–5) | .0006 |
| Antihypertensive(s), Y | 122 (82.4%) | 120 (92.3%) | .0191 |
| Magnesium sulfate, Y | 11 (7.4%) | 12 (9.2%) | .6650 |
| Antiretrovirals, Y | 72 (48.6%) | 77 (59.2%) | .0917 |
| Dexamethasone, Y | 1 (0.7%) | 1 (0.8%) | 1.0000 |
| <i>Pregnancy outcomes</i> | | | |
| Clinic-to-delivery interval, d | 36 (11–83) | 10 (1–25) | $< .0001$ |
| Gestational age at delivery, wk | 37 (34–40) | 35 (32–36) | $< .0001$ |
| Preterm birth, Y | 81 (54.7%) | 110 (84.6%) | $< .0001$ |
| Cesarean delivery, Y | 41 (27.7%) | 43 (33.1%) | .3608 |
| Birth weight, kg | 3.1 (2.7–3.4) (n = 134) | 2.5 (2.0–3.0) (n = 108) | $< .0001$ |
| Maternal mortality, Y | 2 (1.4%) (missing = 13) | 1 (0.8%) (missing = 7) | 1.0000 |
| Perinatal and late neonatal mortality, Y | 14 (9.6%) | 37 (28.5%) | < 0.0001 |
| intrauterine fetal death, Y | 9 (6.1%) | 30 (23.1%) | $< .0001$ |
| neonatal death < 28 d, Y | 5 (3.6%) (n = 139) | 7 (7.0%) (n = 100) | .2475 |




Fig. 1. (a) Time from clinic-to-delivery by placental growth factor concentration dichotomized between normal placental growth factor (≥ 100 pg/ml; median 10 days (blue)) and low placental growth factor (< 99 pg/ml; median 36 days (red)). (b) Gestational age at delivery by placental growth factor concentration dichotomized between normal placental growth factor (≥ 100 pg/ml; median 37 weeks) and low placental growth factor (< 99 pg/ml; median 35 weeks). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 2. Area under the receiver operator curve for placental growth factor in predicting intrauterine fetal death (IUF; purple) and perinatal mortality up to 28 days (PNM; blue). A maternal plasma placental growth factor concentration < 41.8 pg/ml has 76.92% (95% confidence interval (CI) 60.67–88.87%) sensitivity, 78.2% (95% CI 72.5–83.3%) specificity, with a positive likelihood ratio (LR+) of 3.54 for intrauterine fetal death, and PIGF < 39.7 pg/ml a 66.7% (95% CI 52.1–79.2%) sensitivity, 79.7% (73.9–84.8%) specificity and LR+ of 3.29 for perinatal mortality. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

68.0–79.5%) in the prediction of intrauterine fetal death.

4. Discussion

In this implementation study, we have determined that among women with preeclampsia who attended prenatal clinics in Maputo, Mozambique, the introduction of a package of care, including the use of PIGF, was associated with both an increased detection of preeclampsia and an increased number of transfers of care. In addition, low maternal plasma PIGF identified women destined to deliver soon and have more complicated pregnancies, as determined previously using masked PIGF

results [8]. Also, we have determined that maternal plasma PIGF < 40 – 50 pg/ml identifies a group of women at exceptionally high risk for suffering an intrauterine fetal death (32.6% of women with PIGF < 50 pg/ml).

The incidence of suspected preeclampsia in intervention sites was as anticipated from the literature [12]; it is almost certain that the diagnosis was missed in a number of women in control sites. Due to probable incomplete identification of women with suspected preeclampsia in the control sites, direct comparison of the performance of the PIGF assay in terms of reducing the incidence of preeclampsia-related adverse pregnancy outcomes could not be assessed. However, women in the intervention sites were almost twice as likely to be referred to higher levels of care than were women in control sites. The identification of women with pregnancies complicated by preeclampsia and responding to precision risk assessment using PIGF, as achieved in the intervention sites, are critical steps towards reducing direct maternal deaths due to pregnancy hypertension [13].

Incomplete knowledge of the detailed clinical characteristics and outcomes of women who attended for prenatal visits in the control sites is the major limitation of this pragmatic operational pilot study. In addition, the level of confidence in these results might have been improved had a stepped-wedge implementation trial design been used [14].

The exact threshold for raising specific intrauterine fetal death concern requires specific hypothesis-driven research in both general populations and targeted high-risk populations (e.g., preeclampsia, fetal growth restriction, previous intrauterine fetal death) of women. If testing for maternal PIGF can be converted into a whole blood point-of-care assay, we believe that there is great potential for this biomarker of the imperfectly performing placenta to be used at scale to reduce the burden of intrauterine fetal death. Currently, in less-developed settings without access to sophisticated Doppler ultrasound, we believe that a maternal plasma PIGF < 50 pg/ml should be considered as a strong indication for initiating delivery.

Although the median number of prenatal care visits was the same in women with normal and low PIGF (median number of visits: 3), there was a significant increase in the number of visits in the low PIGF group as a whole ($p = .0006$). This is likely to be due to an appropriate response by the woman and her care providers' knowledge about her low PIGF status, although these low PIGF women remained pregnant for about one-third of the time (median: 14 days) than did women with normal PIGF (median: 41 days).

Two hundred and forty-two (87.1%) women with suspected

preeclampsia in the intervention cohort received antihypertensive agents, with a trend for more in the low PIGF group ($p = .0191$). This probably reflects higher systolic and diastolic blood pressure readings at the recruitment prenatal visit. However, as any severe hypertension confers as much risk to a pregnancy as the diagnosis of preeclampsia [15], blood pressure should be normalized in all pregnancies complicated by hypertension, using the CHIPS Trial tight control decision algorithm [16]. In settings such as these, in which all three delays that contribute to maternal death are operating, tight control (i.e., targeting a diastolic blood pressure of 85 mm Hg, and responding to any systolic blood pressure ≥ 160 mm Hg) is likely to have benefits beyond those observed in the main CHIPS Trial. Four hundred and sixty-three of the 981 women in CHIPS developed preeclampsia. The preferential use of methyldopa is consistent with knowledge of availability, cost, improved pregnancy outcomes and neurodevelopmental reassurance to seven years of age [16–19].

Although known to be the optimal agent for both the prevention and treatment of eclampsia [20–23], there was very low use of magnesium sulfate in this cohort (4.7% of hypertensive women overall), even though care providers were informed of the PIGF results, and low PIGF is known to identify women at greater risk for adverse events (5;8;9). It is incumbent on those introducing such a new package of care to ensure vertical integration of the health system and that effective messaging around the new technology crosses all levels of the health system to modify caregiving behavior. Unfortunately, we were not able to determine with certainty the incidence of eclampsia within the cohort. Therefore, whether or not low PIGF should be a specific indication for magnesium sulfate use remains uncertain.

The low rate of use of antenatal corticosteroids (0.7%) in this cohort of women is consistent with the findings in our previous Maputo-based study [8] in which only two of 494 women (0.4%) who delivered prior to 35⁺0 weeks received corticosteroids (data previously unpublished). Knowledge of low PIGF status did not change the behavior of care providers between the two studies. It should be noted that the Mozambique Ministry of Health has only recently actively implemented the use of antenatal corticosteroids for fetal lung maturation (train-the-trainers workshop, June 5–7, 2017). In addition, the publication of the ACT cluster-randomized trial in 2015 [24] may have impeded corticosteroid use in this setting where most women have somewhat uncertain dates.

4.1. Perspectives

There has been increasing evidence for the role of time-of-disease maternal plasma PIGF in identifying incremental maternal and perinatal risks in pregnancies complicated by placental disorders (i.e., preeclampsia, fetal growth restriction and a large proportion of intrauterine fetal death), including in the similar settings in Maputo. To our knowledge, this is the first study to assess the impact of PIGF on clinical practice and outcomes in a less-developed country setting. We have identified that introducing PIGF into clinical care in antenatal clinics is associated with increased identification of women who are deemed to require transfer to higher levels of care. In addition, we have confirmed the ability of low PIGF, measured at time-of-disease, to identify women with pregnancies complicated by preeclampsia who are at increased risk of adverse events. Also, we have identified that a PIGF threshold of 40–50 pg/ml identifies a group of hypertensive pregnant women with a one-third risk of losing their fetus to stillbirth. This requires elucidation. This operational pilot provides additional insights to support the creation of a manual of procedures and recommendations for the scale up of the PIGF test to support the time-of-disease assessment of women with suspected preeclampsia, and screening for stillbirth risk, in high-risk pregnancies in Mozambique.

Acknowledgements

We wish to acknowledge Suraia Marcarenhas (General Nurse) and Valdemira Alda Andrade (Maternal Child Health Nurse) for their roles in day-to-day data gathering and clinical site support. In addition, we wish to thank the clinical advisory board: Professor David Hall (Stellenbosch University), Professor James M Roberts (Magee Women's Research Institute, University of Pittsburgh), Professor Andrew Shennan (King's College London), Dr Augusto Cesar Macome (Hospital Central da Beira).

Sources of funding

The authors are grateful for project funding received from the Government of Flanders (PIGF testing) and Irish Aid Mozambique. We gratefully acknowledge the donation of Microlife AG BP devices and batteries, and urinary dipsticks by the Clinton Health Access Initiative, Maputo.

Disclosures

P. von Dadelszen has been a paid consultant to Alere International. The other authors report no conflicts.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.preghy.2017.12.005>.

References

- [1] B.W. Mol, C.T. Roberts, S. Thangaratnam, L.A. Magee, C.J. de Groot, G.J. Hofmeyr, Pre-eclampsia, *Lancet* 5 (387) (2016) 999–1011.
- [2] L. Say, D. Chou, A. Gemmill, O. Tuncalp, A.B. Moller, J. Daniels, et al., Global causes of maternal death: a WHO systematic analysis, *Lancet Glob. Health* 2 (6) (2014) e323–e333.
- [3] S.J. Benton, Y. Hu, F. Xie, K. Kupfer, S.W. Lee, L.A. Magee, et al., Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays, *Am. J. Obstet. Gynecol.* 205 (5) (2011) 469–e1–8.
- [4] K. Bramham, P.T. Seed, L. Lightstone, C. Nelson-Piercy, C. Gill, P. Webster, et al., Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease, *Kidney Int.* 89 (4) (2016) 874–885.
- [5] L.C. Chappell, S. Duckworth, P.T. Seed, M. Griffin, J. Myers, L. Mackillop, et al., Diagnostic accuracy of placental growth factor in women with suspected pre-eclampsia: a prospective multicenter study, *Circulation* 128 (19) (2013) 2121–2131.
- [6] R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, B.P. Sachs, et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, *N. Engl. J. Med.* 355 (10) (2006) 992–1005.
- [7] A.C. Staff, S.J. Benton, P. von Dadelszen, J.M. Roberts, R.N. Taylor, R.W. Powers, et al., Redefining preeclampsia using placenta-derived biomarkers, *Hypertension* 61 (5) (2013) 932–942.
- [8] U.V. Ukah, F. Mbofana, B.M. Rocha, O. Loquiha, C. Mudenyanga, M. Usta, et al., Diagnostic performance of placental growth factor in women with suspected preeclampsia attending antenatal facilities in Maputo, Mozambique, *Hypertension* 69 (3) (2017) 469–474.
- [9] S.J. Benton, L.M. McCowan, A.E. Heazell, D. Gynspan, J.A. Hutcheon, C. Senger, et al., Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction, *Placenta* 42 (2016) 1–8.
- [10] M.S. Bauer, L. Damschroder, H. Hagedorn, J. Smith, A.M. Kilbourne, An introduction to implementation science for the non-specialist, *BMC Psychol.* 16 (3) (2015) 32.
- [11] A.L. Tranquilli, G. Dekker, L. Magee, J. Roberts, B.M. Sibai, W. Steyn, et al., The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP, *Pregnancy Hypertens.* 4 (2) (2014) 97–104.
- [12] J.A. Hutcheon, S. Lisonkova, K.S. Joseph, Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy, *Best Pract. Res. Clin. Obstet. Gynaecol.* 25 (4) (2011) 391–403.
- [13] P. von Dadelszen, L.A. Magee, Pre-eclampsia: an update, *Curr. Hypertens. Rep.* 16 (8) (2014) 454.
- [14] K. Hemming, T.P. Haines, P.J. Chilton, A.J. Girling, R.J. Lilford, The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting, *BMJ* 6 (350) (2015) h391.
- [15] L.A. Magee, P. von Dadelszen, J. Singer, T. Lee, E. Rey, S. Ross, et al., The CHIPS randomized controlled trial (Control of Hypertension in Pregnancy Study): is severe

- hypertension just an elevated blood pressure? *Hypertension* 68 (5) (2016) 1153–1159.
- [16] L.A. Magee, P. von Dadelszen, E. Rey, S. Ross, E. Asztalos, K.E. Murphy, et al., Less-tight versus tight control of hypertension in pregnancy, *N. Engl. J. Med.* 372 (5) (2015) 407–417.
- [17] J. Cockburn, V.A. Moar, M. Ounsted, C.W. Redman, Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children, *Lancet* 1 (8273) (1982) 647–649.
- [18] S. Lalani, T. Firoz, L.A. Magee, D. Sawchuck, B. Payne, R. Gordon, et al., Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists, *J. Obstet. Gynaecol. Can.* 35 (3) (2013) 215–223.
- [19] L.A. Magee, P. von Dadelszen, J. Singer, T. Lee, E. Rey, S. Ross, et al., Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial, *BJOG* 123 (7) (2016) 1143–1151.
- [20] L. Duley, D.J. Henderson-Smart, G.J. Walker, D. Chou, Magnesium sulphate versus diazepam for eclampsia, *Cochrane Database Syst. Rev.* 8 (12) (2010) CD000127.
- [21] L. Duley, A.M. Gulmezoglu, D.J. Henderson-Smart, D. Chou, Magnesium sulphate and other anticonvulsants for women with pre-eclampsia, *Cochrane Database Syst. Rev.* 10 (11) (2010) CD000025.
- [22] L. Duley, D.J. Henderson-Smart, D. Chou, Magnesium sulphate versus phenytoin for eclampsia, *Cochrane Database Syst. Rev.* 6 (10) (2010) CD000128.
- [23] L. Duley, A.M. Gulmezoglu, D. Chou, Magnesium sulphate versus lytic cocktail for eclampsia, *Cochrane Database Syst. Rev.* 8 (9) (2010) CD002960.
- [24] F. Althabe, J.M. Belizan, E.M. McClure, J. Hemingway-Foday, M. Berrueta, A. Mazzone, et al., A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial, *Lancet* 385 (9968) (2015) 629–639.